Management ChangeMay 15, 2026, 04:09 PM
Indivior Eliminates Chief Scientific Officer Role; Dr. Heidbreder Departs
AI Summary
Indivior Pharmaceuticals, Inc. announced the elimination of the Chief Scientific Officer position, effective June 1, 2026, leading to the termination of Dr. Christian Heidbreder's employment on December 31, 2026. Additionally, the company held its annual meeting of stockholders on May 13, 2026. Shareholders elected all eight director nominees, approved executive compensation on an advisory basis, and indicated a preference for annual Say-on-Pay votes. PricewaterhouseCoopers LLP US was also ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Key Highlights
- Indivior eliminated the Chief Scientific Officer position effective June 1, 2026.
- Dr. Christian Heidbreder's employment as CSO will terminate on December 31, 2026.
- All eight director nominees were elected at the May 13, 2026, annual meeting.
- Shareholders approved executive officer compensation (Say-on-Pay) with 90,364,566 votes For.
- Shareholders voted for an annual frequency for Say-on-Pay votes with 91,848,954 votes For 1 Year.
- PricewaterhouseCoopers LLP US was ratified as the independent auditor for 2026.
Price Impact
More from INDV